CSI Market
Sign In | Register

Seres Therapeutics Inc (MCRB) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access MCRB quarterly Cash Flow →
Observing cash flow movements over recent quarters helps explain how Seres Therapeutics Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income5.70
Depreciation & amortization4.13
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Long-Lived Assets to be Disposed of0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment-0.19
Share-based Compensation10.84
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Fair Value Option Changes In Fair Value Gain Loss-
Payment Of License Fees In Common Stock Warrant-
Amortization Of Operating Lease Asset-
Increase Decrease In Contract With Customer Liability-
Increase Decrease In Operating Lease Liabilities-8.67
Noncash Interest Expense-
Profit Loss From Research Agreement Related Party-
Increase Decrease In Defered Income Related Party-
Collaboration Profit Loss Related To Pre Launch Activities-
Collaboration Profit Loss Sharing Related Party-
Increase Decrease Accounts Receivable Due From S P N- Related Party1.71
Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets8.42
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.16
Increase (Decrease) in Accounts Payable-2.40
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-18.26
Discontinued operations0.00
Net Cash flow from Operating Activities1.12
Investing Activities
Capital Expenditures-0.25
Sale of Capital Items0.21
Payments to Acquire Short-term Investments0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments For Restricted Investments-
Proceeds From Sale Of Restricted Investment-
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.04
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.73
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Exercise Of Stock Options And Common Stock Warrants-
Proceeds From Issuance Of Convertible Preferred Stock Net Of Issuance Costs-
Proceeds From Issuance Of Common And Restricted Stocks-
Proceeds From Issuance Of Common Stock And Restricted Common Stock-
Proceeds From At The Market Equity Offering-
Proceeds From Securities Purchase Agreement Net Of Issuance Costs Related Party-
Proceeds From At The Market Equity Offering Net Of Commissions-
Proceeds From Issuance Of Common Stock From At The Market Equity Offering13.17
Proceeds From Related Party Securities-
Proceeds From Securities Purchase Agreement Related Party-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities13.90
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow1.08
Total Cash Flow14.97
4 historic quarters locked

Sign in to unlock the full Seres Therapeutics Inc cash flow history.

Sign In Create Free Account

About Seres Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-103276

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License